Research programme: flupirtine-based therapeutics - MEDA
Latest Information Update: 19 Aug 2016
At a glance
- Originator Meda
- Mechanism of Action KCNQ potassium channel agonists; NMDA receptor antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Neuroprotection
Most Recent Events
- 05 Aug 2016 Meda has been acquired by Mylan
- 16 Jul 2016 No recent reports of development identified for preclinical development in Neuroprotection in Sweden